Guardiome in 100 Words.
Once upon a time, a young man, a cancer survivor, wanted to understand his own DNA to see if he would relapse. He looked for a whole-genome sequencing service, only to find ones that were difficult, incomplete, and insecure. "Why is it so hard to get my whole-genome securely sequenced?" he wondered. He went back to the lab and told his friends. "Let’s start an awesome whole-genome sequencing company," he said. "Let’s do it in a private and secure way," said his Fiancée. "Let’s also build powerful software for people to explore their genome," said others. Eureka! Guardiome was born.
Press & Media
"Guardiome provides its whole genome sequencing service to consumers on a personal device that's not connected to the internet, which may allow for stronger protection for consumers' privacy and security."
Applied & Translational Genomics -Volume 8, March 2016, Pages 16–22.
“Respect client’s autonomy and their right to know, while providing them with high-quality data so they can use it the way they want.”
GenomeWeb - December 29th, 2015.
The company also develops its own gene information application... The latest research in gene science is provided in the application. Each client's Genome Vault has a unique ID... to ensure that only users can see [their] genetic information.
G2 - February 1st, 2016
Laura Niklason, MD, PhD
Biomedical Engineering, Yale University
Dr. Niklason is a Professor at Yale University in Biomedical Engineering and Anesthesia. In 2005, Dr. Niklason founded (“Humacyte, Inc.”), which is working to bring engineered tissue replacements to patients. For her ingenuity in artery engineering, Dr. Niklason was named one of 19 “Innovators for the Next Century” by US News and World Report in 2001. Dr. Niklason’s lab was one of the first to engineer whole lung tissue that could exchange gas in vivo and this work was cited as one of the top 50 most important inventions of the year by Time Magazine in 2010. She was inducted into the National Academy of Inventors in 2014 and was elected to the National Academy of Medicine in 2015. Dr. Niklason received her PhD in Biophysics from the University of Chicago and her MD from the University of Michigan. She was on the faculty at Duke University where she remained from 1998-2005, before moving to Yale.
Trey Ideker, PhD
Department of Medicine, University of California, San Diego
Dr. Ideker is a network biology expert and the creator of Cytoscape, a popular network analysis platform which has been cited >12,000 times. Dr. Ideker is a Professor of Genetics in the Department of Medicine at the University of California at San Diego. He serves as Director of the National Resource for Network Biology and Director of the San Diego Center for Systems Biology. He is also an Adjunct Professor of Computer Science and Bioengineering at UCSD and a member of Moores Cancer Center. He is a fellow of both the American Association for the Advancement of Science and the American Institute for Medical and Biological Engineering. He was named one of the Top 10 Innovators of 2006 by Technology Review magazine and was the recipient of the 2009 Overton Prize from the International Society for Computational Biology.
Dov Greenbaum, JD, PhD
Department of Molecular Biophysics and Biochemistry, Yale University
Dr. Greenbaum is a leading voice on the ethical, legal, and social implications of genomic developments in America. Dov is the Director of the Zvi Meitar Institute for Legal Implications of Emerging Technologies; concurrently, he is also an Assistant Professor in the Department of Molecular Biophysics and Biochemistry at Yale University School of Medicine (adj). Dov obtained his degrees and post-doctoral fellowships at Yale University, University of California, Berkeley, ETH Zurich and Stanford University. In addition to his academic affiliation and training, he is an intellectual property attorney (California & USPTO) with experience in the field of pharmaceutical litigation, as well as hitech and biotech patent drafting and prosecution.